StreetAlpha.app
Home › Stocks › CLLS

Cellectis S.A. (CLLS)

$1.06
▲ +1.92%
LAST CLOSE · NOV 17

Cellectis develops cell therapies for cancer and genetic diseases using gene editing, and licenses its technology to drug developers. It last closed at $1.06 on Nov 17, up 1.92% on the day. The average 12-month price target from 3 analysts is $4.10 (+286.8% from the last close), with a high of $8.00 and a low of $1.30. Analyst consensus is Hold, based on the latest ratings from 3 firms (1 buy, 1 hold, 1 sell).

AI Auto Pilots
Is CLLS in one of our four AI portfolios? Sign in free to see

Key Stats

Fiscal 2025
Results
Revenue
$72.9M
+75.8% vs a year ago
Net income
−$67.6M
−92.7% margin
Free cash flow
−$41.8M
−57.2% margin
Operating margin
−45.3%
−$33.1M operating income
Balance sheet
Cash & equivalents
$61.5M
At Dec 31
Shareholder equity
$75.9M
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $30.3M$30.3MFY2021FY2022: $19.2M$19.2MFY2022FY2023: $755K$755KFY2023FY2024: $41.5M$41.5MFY2024FY2025: $72.9M$72.9MFY2025

From CLLS's SEC filings, latest 20-F for the period ending Dec 31, 2025 (filed Mar 20). Per share figures are left out because the US listing can represent a different number of shares.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Hold
Based on 3 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Hold
3firms
1 Buy1 Hold1 Sell
Each firm's latest rating on CLLS in the past 90 days
Average 12-month target
$4.10
▲ 286.8% upside

Based on 3 analysts who set a price target on CLLS in the past 90 days. The average target is $4.10, with a high of $8.00 and a low of $1.30, compared with the last close of $1.06.

Low $1.30Avg $4.10High $8.00
Blue marker: last close $1.06
Highest target$8.00
Average target$4.10
Lowest target$1.30
Latest rating changes
BarclaysDowngrade
Sep 16Sell$9 → $1.30
Wells FargoMaintained
Sep 15Hold$3
BairdMaintained
Sep 15Buy$8
BarclaysInitiated
May 28Buy$9
DateFirmActionRatingPrice target
Sep 16BarclaysDowngradeSell$9 → $1.30
Sep 15Wells FargoMaintainedHold$3
Sep 15BairdMaintainedBuy$8
May 28BarclaysInitiatedBuy$9
Loading…

Technical Analysis

CLLS · as of the Nov 17 close · updated after every close
Downtrend

The stock is 4% below its 20 day and 28% below its 50 day average. It is 173% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 43). The nearest support is the Pivot at $1.05, and the nearest resistance the Pivot R1 at $1.09.

Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityHigh, 13.1%/day
Key levels
$5.4552 week high+414.2%
$2.89200 day average+172.6%
$2.19100 day average+106.6%
$1.3650 day average+28.3%
$1.25Swing high (Nov 4)+17.9%
$1.1020 day average+3.8%
$1.09Pivot R1+2.8%
$1.06Last close
$1.05Pivot−0.9%
$1.03Pivot S1−2.8%
$1.00Swing low (Nov 5)−5.7%
$0.8852 week low−17.0%
Indicators
RSI (14)42.88Middle of its rangeNeutral
MACD-0.07Above its signal lineBullish
Stochastic19.0Near the bottom of its rangeOversold
ADX (14)29.6Trending down
Williams %R-88.7Oversold below −80, overbought above −20Oversold
CCI (20)-41.8Oversold below −100, overbought above 100Neutral
Rate of change−2.8%Change over 10 sessionsBearish
ATR (14)$0.14Typical daily range, 13.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for CLLS

What happened before

See how CLLS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow CLLS usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How CLLS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2015.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in CLLS in the last 90 days.

Loading…

See today’s whale options flow across the market →

CLLS Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲12 buying vs 9 selling
  • ●Shares held by funds +0.3%
  • ▲Funds holding +4
  • ●No superinvestor moves
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding3127+14.8%
In funds' top 1001−100.0%
Held by funds–––
New / increased8 / 43 / 1+200.0%
Reduced / sold out4 / 58 / 8−43.8%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See CLLS institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CLLS is in one of them and how their past CLLS trades turned out.

CLLS in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered CLLS in an article yet. Here's the latest on the wider market.

About Cellectis S.A.

Cellectis is a biotechnology company based in Paris, France, that develops cell and gene therapies using gene editing. Its main focus is cancer treatments made from CAR T cells taken from healthy donors, which can be produced in batches and shipped as ready to use products rather than made for each patient. The company also develops gene therapies for genetic diseases and licenses its technology to drug developers such as AstraZeneca, Allogene, Servier and Iovance.

Headquarters
Paris, Lle-De-France
Founded
1999